Back to search

Peptide record

TPDB42596

U3 Anticancer standard
11 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42596
U3
Anticancer
Cancer-related peptides
CancerPPD 2.0 dbACP
standard
No
A 11-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0 and dbACP, with an available 3D structural model.
Sequence
NGSIPATWASL
Physicochemical Analysis
C50H77N13O16
RDCEQHKMFYV
AS
1116.24
6.02
0
0
5
-0
-1.78
0.291
89.09
Mammalian: 1.4 hour Yeast: 3 min E.coli: >10 hour
5500
492.73
4
Residue Composition
number
2
A
0
R
1
N
0
D
0
C
0
E
0
Q
1
G
0
H
1
I
1
L
0
K
0
M
0
F
1
P
2
S
1
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 1 L: 1 K: 0 M: 0 F: 0 P: 1 S: 2 T: 1 W: 1 Y: 0 V: 0
Chemical Descriptors
11
C50H77N13O16
1116.24
6.02
-0
-1.78
0.291
Free
L
Linear
Free
Anticancer
Phoenix dactylifera
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 555 µM
Anticancer
555 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2024

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 517.6 ± 34.86 µM
Anticancer
517.6

Target

Breast Cancer
T-47D
Breast

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2024
Evidence 3 Activity

Activity

IC50
IC50 = 561 µM
Anticancer
561 µM

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2024